Oncimmune Holdings plc

LSE ONC.L

Oncimmune Holdings plc Free Cash Flow Yield on February 05, 2025: -69.46%

Oncimmune Holdings plc Free Cash Flow Yield is -69.46% on February 05, 2025, a -190.11% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Oncimmune Holdings plc 52-week high Free Cash Flow Yield is -19.90% on April 18, 2024, which is 71.35% above the current Free Cash Flow Yield.
Oncimmune Holdings plc 52-week low Free Cash Flow Yield is -69.46% on February 05, 2025, which is 0.00% below the current Free Cash Flow Yield.
Oncimmune Holdings plc average Free Cash Flow Yield for the last 52 weeks is -37.36%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

LSE: ONC.L

Oncimmune Holdings plc

CEO	Mr. Martin John Gouldstone
IPO Date	May 18, 2016
Location	United Kingdom
Headquarters	MediCity
Employees	38
Sector	Healthcare
Industries Biotechnology 3D Printing Big Data Clinical Trials Medical Instruments Pharmaceuticals Robotics Vaccines

Description

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Key trends

Past 5 years